We apply cutting-edge molecular biology technologies such as lentivirus-based RNA interference in the discovery of novel therapeutic entities. This includes new technology development, functional gene discovery and drug target identification, high throughput screening assay development, and novel mechanism of action exploration of pipeline compounds, for the treatment and prevention of cardiovascular and thrombotic disorders.

We are engaged in gene expression, molecular cloning and functional studies performed in vascular cells to develop monoclonal antibodies. We identify gene functions using functional genomics and bioinformatics.